Postchemotherapy and tumor-selective targeting with the la-specific DAB4 monoclonal antibody relates to apoptotic cell clearance

Fares Al-Ejeh, Alexander H. Staudacher, Douglas Smyth, Jocelyn M. Darby, Delphine Denoyer, Chris Tsopelas, Rodney J. Hicks, Michael P. Brown

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Early identification of tumor responses to treatment is crucial for devising more effective and safer cancer treatments. No widely applicable, noninvasive method currently exists for specifically detecting tumor cell death after cytotoxic treatment and thus for predicting treatment outcomes. Methods: We have further characterized the targeting of the murine monoclonal antibody DAB4 specifically to dead tumor cells in vitro, in vivo, and in clinical samples. We found that sustained DAB4 binding to treated cells was closely associated with markers of intrinsic apoptosis and DNA double-strand break formation. In a competition binding assay, DAB4 bound EL4 murine thymic lymphoma cells in preference to the normal counterpart of murine thymocytes. Defective in vivo clearance of apoptotic cells augmented in vivo accumulation of DAB4 in tumors particularly after chemotherapy but was unchanged in normal tissues. Tumor targeting of DAB4 was selective for syngeneic murine tumors and for human tumor xenografts of prostate cancer (PC-3) and pancreatic cancer (Panc-1) before and more so after chemotherapy. Furthermore, DAB4 was shown to bind to dead primary acute lymphoblastic leukemic blasts cultured with cytotoxic drugs and dead epithelial cancer cells isolated from peripheral blood of small cell lung carcinoma patients given chemotherapy. Conclusion: Collectively, these results further demonstrate the selectivity of DAB4 for chemotherapy-induced dead tumor cells. This postchemotherapy selectivity is related to a relative increase in the availability of DAB4-binding targets in tumor tissue rather than in normal tissues. The in vitro findings were translated in vivo to human xenograft models and to ex vivo analyses of clinical samples, providing further evidence of the potential of DAB4 as a marker of tumor cell death after DNA-damaging cytotoxic treatment that could be harnessed as a predictive marker of treatment responses.

LanguageEnglish
Pages772-779
Number of pages8
JournalJournal of Nuclear Medicine
Volume55
Issue number5
DOIs
Publication statusPublished - 1 May 2014
Externally publishedYes

Keywords

  • APOMAB
  • Apoptosis
  • Chemotherapy
  • DAB4
  • La
  • Therapy response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Al-Ejeh, Fares ; Staudacher, Alexander H. ; Smyth, Douglas ; Darby, Jocelyn M. ; Denoyer, Delphine ; Tsopelas, Chris ; Hicks, Rodney J. ; Brown, Michael P. / Postchemotherapy and tumor-selective targeting with the la-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. In: Journal of Nuclear Medicine. 2014 ; Vol. 55, No. 5. pp. 772-779.
@article{f9bd355adf5f4023a76558b0f8352d90,
title = "Postchemotherapy and tumor-selective targeting with the la-specific DAB4 monoclonal antibody relates to apoptotic cell clearance",
abstract = "Early identification of tumor responses to treatment is crucial for devising more effective and safer cancer treatments. No widely applicable, noninvasive method currently exists for specifically detecting tumor cell death after cytotoxic treatment and thus for predicting treatment outcomes. Methods: We have further characterized the targeting of the murine monoclonal antibody DAB4 specifically to dead tumor cells in vitro, in vivo, and in clinical samples. We found that sustained DAB4 binding to treated cells was closely associated with markers of intrinsic apoptosis and DNA double-strand break formation. In a competition binding assay, DAB4 bound EL4 murine thymic lymphoma cells in preference to the normal counterpart of murine thymocytes. Defective in vivo clearance of apoptotic cells augmented in vivo accumulation of DAB4 in tumors particularly after chemotherapy but was unchanged in normal tissues. Tumor targeting of DAB4 was selective for syngeneic murine tumors and for human tumor xenografts of prostate cancer (PC-3) and pancreatic cancer (Panc-1) before and more so after chemotherapy. Furthermore, DAB4 was shown to bind to dead primary acute lymphoblastic leukemic blasts cultured with cytotoxic drugs and dead epithelial cancer cells isolated from peripheral blood of small cell lung carcinoma patients given chemotherapy. Conclusion: Collectively, these results further demonstrate the selectivity of DAB4 for chemotherapy-induced dead tumor cells. This postchemotherapy selectivity is related to a relative increase in the availability of DAB4-binding targets in tumor tissue rather than in normal tissues. The in vitro findings were translated in vivo to human xenograft models and to ex vivo analyses of clinical samples, providing further evidence of the potential of DAB4 as a marker of tumor cell death after DNA-damaging cytotoxic treatment that could be harnessed as a predictive marker of treatment responses.",
keywords = "APOMAB, Apoptosis, Chemotherapy, DAB4, La, Therapy response",
author = "Fares Al-Ejeh and Staudacher, {Alexander H.} and Douglas Smyth and Darby, {Jocelyn M.} and Delphine Denoyer and Chris Tsopelas and Hicks, {Rodney J.} and Brown, {Michael P.}",
year = "2014",
month = "5",
day = "1",
doi = "10.2967/jnumed.113.130559",
language = "English",
volume = "55",
pages = "772--779",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

Postchemotherapy and tumor-selective targeting with the la-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. / Al-Ejeh, Fares; Staudacher, Alexander H.; Smyth, Douglas; Darby, Jocelyn M.; Denoyer, Delphine; Tsopelas, Chris; Hicks, Rodney J.; Brown, Michael P.

In: Journal of Nuclear Medicine, Vol. 55, No. 5, 01.05.2014, p. 772-779.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Postchemotherapy and tumor-selective targeting with the la-specific DAB4 monoclonal antibody relates to apoptotic cell clearance

AU - Al-Ejeh, Fares

AU - Staudacher, Alexander H.

AU - Smyth, Douglas

AU - Darby, Jocelyn M.

AU - Denoyer, Delphine

AU - Tsopelas, Chris

AU - Hicks, Rodney J.

AU - Brown, Michael P.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Early identification of tumor responses to treatment is crucial for devising more effective and safer cancer treatments. No widely applicable, noninvasive method currently exists for specifically detecting tumor cell death after cytotoxic treatment and thus for predicting treatment outcomes. Methods: We have further characterized the targeting of the murine monoclonal antibody DAB4 specifically to dead tumor cells in vitro, in vivo, and in clinical samples. We found that sustained DAB4 binding to treated cells was closely associated with markers of intrinsic apoptosis and DNA double-strand break formation. In a competition binding assay, DAB4 bound EL4 murine thymic lymphoma cells in preference to the normal counterpart of murine thymocytes. Defective in vivo clearance of apoptotic cells augmented in vivo accumulation of DAB4 in tumors particularly after chemotherapy but was unchanged in normal tissues. Tumor targeting of DAB4 was selective for syngeneic murine tumors and for human tumor xenografts of prostate cancer (PC-3) and pancreatic cancer (Panc-1) before and more so after chemotherapy. Furthermore, DAB4 was shown to bind to dead primary acute lymphoblastic leukemic blasts cultured with cytotoxic drugs and dead epithelial cancer cells isolated from peripheral blood of small cell lung carcinoma patients given chemotherapy. Conclusion: Collectively, these results further demonstrate the selectivity of DAB4 for chemotherapy-induced dead tumor cells. This postchemotherapy selectivity is related to a relative increase in the availability of DAB4-binding targets in tumor tissue rather than in normal tissues. The in vitro findings were translated in vivo to human xenograft models and to ex vivo analyses of clinical samples, providing further evidence of the potential of DAB4 as a marker of tumor cell death after DNA-damaging cytotoxic treatment that could be harnessed as a predictive marker of treatment responses.

AB - Early identification of tumor responses to treatment is crucial for devising more effective and safer cancer treatments. No widely applicable, noninvasive method currently exists for specifically detecting tumor cell death after cytotoxic treatment and thus for predicting treatment outcomes. Methods: We have further characterized the targeting of the murine monoclonal antibody DAB4 specifically to dead tumor cells in vitro, in vivo, and in clinical samples. We found that sustained DAB4 binding to treated cells was closely associated with markers of intrinsic apoptosis and DNA double-strand break formation. In a competition binding assay, DAB4 bound EL4 murine thymic lymphoma cells in preference to the normal counterpart of murine thymocytes. Defective in vivo clearance of apoptotic cells augmented in vivo accumulation of DAB4 in tumors particularly after chemotherapy but was unchanged in normal tissues. Tumor targeting of DAB4 was selective for syngeneic murine tumors and for human tumor xenografts of prostate cancer (PC-3) and pancreatic cancer (Panc-1) before and more so after chemotherapy. Furthermore, DAB4 was shown to bind to dead primary acute lymphoblastic leukemic blasts cultured with cytotoxic drugs and dead epithelial cancer cells isolated from peripheral blood of small cell lung carcinoma patients given chemotherapy. Conclusion: Collectively, these results further demonstrate the selectivity of DAB4 for chemotherapy-induced dead tumor cells. This postchemotherapy selectivity is related to a relative increase in the availability of DAB4-binding targets in tumor tissue rather than in normal tissues. The in vitro findings were translated in vivo to human xenograft models and to ex vivo analyses of clinical samples, providing further evidence of the potential of DAB4 as a marker of tumor cell death after DNA-damaging cytotoxic treatment that could be harnessed as a predictive marker of treatment responses.

KW - APOMAB

KW - Apoptosis

KW - Chemotherapy

KW - DAB4

KW - La

KW - Therapy response

UR - http://www.scopus.com/inward/record.url?scp=84901368017&partnerID=8YFLogxK

U2 - 10.2967/jnumed.113.130559

DO - 10.2967/jnumed.113.130559

M3 - Article

VL - 55

SP - 772

EP - 779

JO - Journal of Nuclear Medicine

T2 - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -